{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:14:54Z","timestamp":1791648894865,"version":"4.3.4"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R61-NS113341"],"award-info":[{"award-number":["R61-NS113341"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011238","name":"Lions Clubs International Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007745","name":"Massachusetts Lions Eye Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007745","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006954","name":"Tufts Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jtos.2020.12.003","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T23:00:18Z","timestamp":1610578818000},"page":"33-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Low-dose naltrexone is effective and well-tolerated for modulating symptoms in patients with neuropathic corneal pain"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6764-7939","authenticated-orcid":false,"given":"Gabriela","family":"Dieckmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3164-6336","authenticated-orcid":false,"given":"M. Cuneyt","family":"Ozmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan C.","family":"Engert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9313-2939","authenticated-orcid":false,"given":"Pedram","family":"Hamrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtos.2020.12.003_bib1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0014-4835(03)00050-2","article-title":"Corneal nerves: structure, contents and function","volume":"76","author":"Muller","year":"2003","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jtos.2020.12.003_bib2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1542-0124(12)70112-X","article-title":"Nerves and sensations from the eye surface","volume":"2","author":"Belmonte","year":"2004","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2020.12.003_bib3","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtos.2017.05.002","article-title":"TFOS DEWS II pain and sensation report","volume":"15","author":"Belmonte","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2020.12.003_bib4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/08820538.2015.1114853","article-title":"Understanding neuropathic corneal pain--gaps and current therapeutic approaches","volume":"31","author":"Goyal","year":"2016","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.jtos.2020.12.003_bib5","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.ophtha.2017.08.004","article-title":"Neuropathic corneal pain: approaches for management","volume":"124","author":"Dieckmann","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2020.12.003_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40135-015-0073-9","article-title":"What causes eye pain?","volume":"3","author":"Belmonte","year":"2015","journal-title":"Curr Ophthalmol Rep"},{"key":"10.1016\/j.jtos.2020.12.003_bib7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cell.2009.09.028","article-title":"Cellular and molecular mechanisms of pain","volume":"139","author":"Basbaum","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.jtos.2020.12.003_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neubiorev.2018.02.015","article-title":"Subliminal (latent) processing of pain and its evolution to conscious awareness","volume":"88","author":"Borsook","year":"2018","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.jtos.2020.12.003_bib9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fnins.2012.00136","article-title":"Organization of neural systems for aversive information processing: pain, error, and punishment","volume":"6","author":"Kobayashi","year":"2012","journal-title":"Front Neurosci"},{"key":"10.1016\/j.jtos.2020.12.003_bib10","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1136\/bjophthalmol-2016-309658","article-title":"Evidence of central sensitisation in those with dry eye symptoms and neuropathic-like ocular pain complaints: incomplete response to topical anaesthesia and generalised heightened sensitivity to evoked pain","volume":"101","author":"Crane","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2020.12.003_bib11","doi-asserted-by":"crossref","unstructured":"Dieckmann G, Koseoglu DN, Jamali A, Lopez MJ, Moein HR, Hamrah P. Demographics and risk factors of patients with neuropathic corneal pain. Poster presented at: American Academy of Ophthalmology; November 11-14, 2017; New Orleans, LA PO058.","DOI":"10.1016\/j.ophtha.2017.08.004"},{"issue":"Suppl 2","key":"10.1016\/j.jtos.2020.12.003_bib12","doi-asserted-by":"crossref","first-page":"S307","DOI":"10.1097\/ICL.0000000000000463","article-title":"Neuropathic-like ocular pain and nonocular comorbidities correlate with dry eye symptoms","volume":"44","author":"Chang","year":"2018","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.jtos.2020.12.003_bib13","first-page":"138","article-title":"Corneal pain has a negative impact on the quality of life of patients with neuropathic corneal pain","volume":"59","author":"Lopez","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2020.12.003_bib14","first-page":"82","article-title":"Low-dose naltrexone (LDN)-Review of therapeutic utilization","volume":"6","author":"Toljan","year":"2018","journal-title":"Med Sci"},{"key":"10.1016\/j.jtos.2020.12.003_bib15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10067-014-2517-2","article-title":"The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain","volume":"33","author":"Younger","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jtos.2020.12.003_bib16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tins.2012.11.002","article-title":"Opioid receptors: distinct roles in mood disorders","volume":"36","author":"Lutz","year":"2013","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.jtos.2020.12.003_bib17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.mehy.2008.06.048","article-title":"Low-dose naltrexone for disease prevention and quality of life","volume":"72","author":"Brown","year":"2009","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.jtos.2020.12.003_bib18","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1177\/1049909119838974","article-title":"Pharmacology update: low-dose naltrexone as a possible nonopioid modality for some chronic, nonmalignant pain syndromes","volume":"36","author":"Trofimovitch","year":"2019","journal-title":"Am J Hosp Palliat Care"},{"key":"10.1016\/j.jtos.2020.12.003_bib19","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/phar.2086","article-title":"The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, crohn's disease, and other chronic pain disorders","volume":"38","author":"Patten","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jtos.2020.12.003_bib20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10067-014-2517-2","article-title":"The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain","volume":"33","author":"Younger","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jtos.2020.12.003_bib21","first-page":"790","article-title":"Off-label, low-dose naltrexone for refractory painful diabetic neuropathy","volume":"17","author":"Hota","year":"2016","journal-title":"Pain Med"},{"key":"10.1016\/j.jtos.2020.12.003_bib22","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.ophtha.2016.03.006","article-title":"Validity and reliability of a novel ocular pain assessment survey (OPAS) in quantifying and monitoring corneal and ocular surface pain","volume":"123","author":"Qazi","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2020.12.003_bib23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jclinepi.2018.05.007","article-title":"Minimum clinically important differences in chronic pain vary considerably by baseline pain and methodological factors: systematic review of empirical studies","volume":"101","author":"Olsen","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jtos.2020.12.003_bib24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.jtos.2020.12.003_bib25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.jtos.2020.12.003_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11916-009-0009-x","article-title":"Pain outcomes: a brief review of instruments and techniques","volume":"13","author":"Younger","year":"2009","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.jtos.2020.12.003_bib27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jclinepi.2018.05.007","article-title":"Minimum clinically important differences in chronic pain vary considerably by baseline pain and methodological factors: systematic review of empirical studies","volume":"101","author":"Olsen","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jtos.2020.12.003_bib28","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/pme.12345","article-title":"Off-label, low-dose naltrexone for refractory chronic low back pain","volume":"15","author":"Ghai","year":"2014","journal-title":"Pain Med"},{"key":"10.1016\/j.jtos.2020.12.003_bib29","first-page":"197","article-title":"Low-dose naltrexone: a New therapy option for complex regional pain syndrome type I patients","volume":"20","author":"Sturn","year":"2016","journal-title":"Int J Pharm Compd"},{"key":"10.1016\/j.jtos.2020.12.003_bib30","first-page":"94","article-title":"Low-dose naltrexone therapy for psoriasis","volume":"24","author":"Weinstock","year":"2020","journal-title":"Int J Pharm Compd"},{"key":"10.1016\/j.jtos.2020.12.003_bib31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/17469899.2016.1222905","article-title":"What can photophobia tell us about dry eye?","volume":"11","author":"Galor","year":"2016","journal-title":"Expet Rev Ophthalmol"},{"key":"10.1016\/j.jtos.2020.12.003_bib32","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/bjophthalmol-2014-306280","article-title":"Ocular neuropathic pain","volume":"100","author":"Rosenthal","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2020.12.003_bib33","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/jnen\/61.11.1013","article-title":"Broad expression of Toll-like receptors in the human central nervous system","volume":"61","author":"Bsibsi","year":"2002","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.jtos.2020.12.003_bib34","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3389\/fimmu.2017.00809","article-title":"Naltrexone inhibits IL-6 and TNFalpha production in human immune cell subsets following stimulation with ligands for intracellular toll-like receptors","volume":"8","author":"Cant","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtos.2020.12.003_bib35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/ALN.0000000000002130","article-title":"Neuroinflammation and central sensitization in chronic and widespread pain","volume":"129","author":"Ji","year":"2018","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jtos.2020.12.003_bib36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s13181-015-0512-x","article-title":"Naltrexone: not just for opioids anymore","volume":"12","author":"Sudakin","year":"2016","journal-title":"J Med Toxicol"},{"key":"10.1016\/j.jtos.2020.12.003_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/apc.1995.9.3","article-title":"Efficacy of low dose naltrexone as an immune stabilizing agent for the treatment of HIV\/AIDS","volume":"9","author":"Bihari","year":"1995","journal-title":"AIDS Patient Care"},{"key":"10.1016\/j.jtos.2020.12.003_bib38","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1526-4637.2009.00613.x","article-title":"Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study","volume":"10","author":"Younger","year":"2009","journal-title":"Pain Med"},{"key":"10.1016\/j.jtos.2020.12.003_bib39","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.37734","article-title":"Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels","volume":"65","author":"Younger","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jtos.2020.12.003_bib40","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.mehy.2008.06.048","article-title":"Low-dose naltrexone for disease prevention and quality of life","volume":"72","author":"Brown","year":"2009","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.jtos.2020.12.003_bib41","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1177\/1352458510366857","article-title":"The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial","volume":"16","author":"Sharafaddinzadeh","year":"2010","journal-title":"Mult Scler"},{"key":"10.1016\/j.jtos.2020.12.003_bib42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ana.22006","article-title":"Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis","volume":"68","author":"Cree","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jtos.2020.12.003_bib43","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ana.22006","article-title":"Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis","volume":"68","author":"Cree","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jtos.2020.12.003_bib44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12967-018-1427-5","article-title":"Low dose Naltrexone for induction of remission in inflammatory bowel disease patients","volume":"16","author":"Lie","year":"2018","journal-title":"J Transl Med"},{"issue":"3","key":"10.1016\/j.jtos.2020.12.003_bib45","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/ICL.0000000000000630","article-title":"Oral gabapentinoids and nerve blocks for the treatment of chronic ocular pain","volume":"46","author":"Small","year":"2019","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.jtos.2020.12.003_bib46","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jtos.2017.10.003","article-title":"Efficacy of self-retained cryopreserved amniotic membrane for treatment of neuropathic corneal pain","volume":"16","author":"Morkin","year":"2018","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2020.12.003_bib47","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jtos.2015.01.005","article-title":"Autologous serum tears for treatment of photoallodynia in patients with corneal neuropathy: efficacy and evaluation with in vivo confocal microscopy","volume":"13","author":"Aggarwal","year":"2015","journal-title":"Ocul Surf"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012420301890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012420301890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:39:34Z","timestamp":1761539974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012420301890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":47,"alternative-id":["S1542012420301890"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2020.12.003","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose naltrexone is effective and well-tolerated for modulating symptoms in patients with neuropathic corneal pain","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2020.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}